[go: up one dir, main page]

DK1185279T3 - Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1 - Google Patents

Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1

Info

Publication number
DK1185279T3
DK1185279T3 DK00949114T DK00949114T DK1185279T3 DK 1185279 T3 DK1185279 T3 DK 1185279T3 DK 00949114 T DK00949114 T DK 00949114T DK 00949114 T DK00949114 T DK 00949114T DK 1185279 T3 DK1185279 T3 DK 1185279T3
Authority
DK
Denmark
Prior art keywords
protein
treatment
agents
malignant diseases
tumour cells
Prior art date
Application number
DK00949114T
Other languages
English (en)
Inventor
Per Sonne Holm
Hans-Dieter Royer
Manfred Dietel
Hermann Lage
Axel Ladhoff
Karsten Juerchott
Stephan Bergmann
Karsten Brand
Original Assignee
Per Sonne Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Per Sonne Holm filed Critical Per Sonne Holm
Application granted granted Critical
Publication of DK1185279T3 publication Critical patent/DK1185279T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK00949114T 1999-06-21 2000-06-20 Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1 DK1185279T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929569A DE19929569A1 (de) 1999-06-21 1999-06-21 Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
PCT/DE2000/001978 WO2000078327A2 (de) 1999-06-21 2000-06-20 Mittel zur behandlung maligner erkrankungen unter verwendung von e1a-defizienten adenoviren mit yb-1 abhängiger replikation

Publications (1)

Publication Number Publication Date
DK1185279T3 true DK1185279T3 (da) 2005-05-23

Family

ID=7912815

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00949114T DK1185279T3 (da) 1999-06-21 2000-06-20 Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1

Country Status (8)

Country Link
US (2) US20020086411A1 (da)
EP (1) EP1185279B1 (da)
JP (1) JP2003502378A (da)
AT (1) ATE287722T1 (da)
DE (2) DE19929569A1 (da)
DK (1) DK1185279T3 (da)
ES (1) ES2235917T3 (da)
WO (1) WO2000078327A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216500A1 (en) * 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
WO2002053760A2 (en) * 2000-12-18 2002-07-11 Geron Corporation Chimeric cytolytic viruses for cancer treatment
EP1346058B1 (de) * 2000-12-28 2007-05-02 Per Sonne Holm Adenovirale systeme und deren anwendungen
JP5213298B2 (ja) 2002-05-27 2013-06-19 ホルム，ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
WO2005051430A1 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1689446B1 (de) * 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
DE102004060385A1 (de) * 2004-12-14 2006-07-06 Rwth Aachen Verfahren zur Bestimmung entzündlicher Vorgänge und pharmazeutische Zusammensetzungen zur Behandlung derselben
CA2592699C (en) * 2004-12-31 2023-02-21 Per Sonne Holm Method for reversing multiple resistance in animal cells
AU2010328335B2 (en) * 2009-12-08 2013-09-26 Memorial Sloan-Kettering Cancer Center Method and composition to increase radiation-induced tumor therapeutic effects
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP3198009B1 (en) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2019199859A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4947842A (en) * 1988-09-22 1990-08-14 Medical Engineering And Development Institute, Inc. Method and apparatus for treating tissue with first and second modalities
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
PT931830E (pt) * 1993-02-16 2001-08-30 Onyx Pharma Inc Virus citopaticos para terapia e profilaxia de neoplasia
US6096718A (en) * 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
US20020151461A1 (en) * 1998-02-19 2002-10-17 Hong-Ji Xu Modified retinoblastoma tumor supressor proteins
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors

Also Published As

Publication number Publication date
ATE287722T1 (de) 2005-02-15
US20040265277A1 (en) 2004-12-30
US20020086411A1 (en) 2002-07-04
WO2000078327A3 (de) 2001-05-10
DE50009365D1 (de) 2005-03-03
EP1185279B1 (de) 2005-01-26
JP2003502378A (ja) 2003-01-21
ES2235917T3 (es) 2005-07-16
WO2000078327A2 (de) 2000-12-28
DE19929569A1 (de) 2000-12-28
EP1185279A2 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
EP1481077A4 (en) MITOTIC KINESINE HEMMER
EP1322307A4 (en) METHOD FOR THE TREATMENT OF CELL PROLIFERATION TROUBLES AND VIRUS INFECTIONS
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
EP1435946B8 (en) Linked biaryl compounds
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
WO2006004636A3 (en) Fused heterocyclic kinase inhibitors
EP1137658A4 (en) METHOD FOR MODULATING TUMOR NECROSIS FACTOR -g (a) -INDUCTED EXPRESSION OF CELL ADHESION MOLECULES
DK1742644T3 (da) Terapeutisk sammensætning indeholdende mindst et pyrrolbenzodiazepin-derivat og fludarabin
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
EA200400235A1 (ru) Комбинированная терапия для лечения рака
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
DK1755659T3 (da) Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
DK1105728T3 (da) Modulering af multiple lineage kinase-proteiner
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
DK1276501T3 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
MXPA05011171A (es) Metodos y composiciones que activan cinasas de tirosina para el diagnostico y tratamiento de osteoartritis.
UY26265A1 (es) Compuestos calciolíticos
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
DK1162985T3 (da) Matrixproteinsammensætninger til induktion af apoptose
NO20005548L (no) Mykobakterieinhibitorer